Ligand Pharmaceuticals to buy Pfenex for up to $516m
Under the deal, Ligand Pharmaceuticals will purchase all outstanding shares of Pfenex for $12 per share in cash or $438m in equity value on a fully diluted basis.
Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.
There are no HER3 directed therapies approved for the treatment of NSCLC or any cancer. The frequency of HER3 overexpression in EGFR-mutated NSCLC has been reported to be
The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, in